Lung Adenocarcinoma Clinical Trial
Official title:
Efficacy and Safety of Jing-yuan-kang Granule in the Treatment of Lung Adenocarcinoma
This study is to evaluate the efficacy and safety of Jin-yuan-kang granule in the treatment of lung adenocarcinoma (LUAD) preliminarily, and provide reference for further study.
Lung adenocarcinoma (LUAD) is a type of non-small cell lung cancer (NSCLC) with a rapid
disease progression and poor treatment effect. The LUAD patients have a short median survival
time with 8-11 months. Up to now, chemotherapy is still the first-line treatment for LUAD. PC
protocol (pemetrexed + cisplatin) is most commonly used, which is also recommended by NCCN
guidelines. However, critical side effects have limited the application and efficacy.
Patients will undergo poor quality of life, and the disease will progress rapidly. We still
face the stern situation for the treatment of LUAD. It is urgent to develop new treatment and
management strategies. Our previous study showed that jing-yuan-kang granule has certain
curative effect on LUAD.
This is a multi-certers, randomized, controlled clinical trial to assess the efficacy and
safety of Jing-yuan-kang granule in improving quality of life for LUAD patients. After a
2-week wash-out period, a total of 144 LUAD patients will be randomly assigned into
experimental or control group with a ratio of 1:1. On the basis of that all the participants
will receive PC chemotherapy and symptomatic treatment, the patients in the experimental
group will receive jing-yuan-kang granule with no other treatments for control group. The
primary outcome is quality of life. The secondary outcomes include Karnofsky (KPS) scores,
clinical symptoms, and change of tumor volume. Safety and adverse events will also be
assessed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT02621333 -
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
Recruiting |
NCT05266846 -
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
|
Phase 2 |